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Good concordance of HPV detection
between cervico-vaginal self-samples and
general practitioner-collected samples
using the Cobas 4800 HPV DNA test
Mette Tranberg1,2* , Jørgen Skov Jensen3, Bodil Hammer Bech4, Jan Blaakær5,6, Hans Svanholm7
and Berit Andersen1,2
Abstract
Background: Studies comparing self-samples and clinician-collected samples for high-risk human papillomavirus
(HPV) detection using clinically validated PCR-based HPV DNA assays are limited. We measured the concordance of
HPV detection between home-based self-sampling and general practitioner (GP) sampling using the Cobas 4800
HPV DNA test and studied women’s accept of home-based self-sampling.
Methods: Paired GP-collected samples and cervico-vaginal self-samples were obtained from 213 women aged
30–59 years diagnosed with ASC-US within the cervical cancer screening program. After undergoing cervical
cytology at their GP, the women collected a self-sample with the Evalyn Brush at home and completed a
questionnaire. Both samples were HPV-tested using the Cobas 4800 test. Histology results were available for
those who tested HPV positive in GP-collected samples.
Results: We observed good concordance for HPV detection between self-samples and GP-collected samples
(κ: 0.70, 95% CI: 0.58–0.81). No underlying CIN2+ cases were missed by self-sampling. Women evaluated that
self-sampling was easy (97.2%, 95% CI: 93.9–98.9%) and comfortable (94.8%, 95% CI: 90.9–97.4%).
Conclusions: Home-based self-sampling using the Evalyn Brush and the Cobas 4800 test is an applicable and
reliable alternative to GP-sampling.
Keywords: Self-sampling, Human papillomavirus testing, Cervical cancer screening, Acceptability
Background
DNA tests for HPV testing in cervical cancer screening
have been developed due to the strong causal relation-
ship between persistent cervical infection caused by
high-risk human papillomavirus (HPV) types and cer-
vical cancer and its pre-cancer lesions [1, 2].
Screening based on HPV testing is more sensitive in de-
tecting cervical intraepithelial neoplasia of grade 3 (CIN3)
and cancer than cytology-based screening [3, 4], and
women with a negative HPV test have a lower 5-year risk
of CIN3 and cancer than women with a negative cytology
[5]. An advantage of HPV testing is that, unlike cytology,
it enables women to self-sample cervico-vaginal material
at home (HPV self-sampling), which may improve cervical
cancer screening participation [6].
Studies comparing self-samples and clinician-collected
samples for HPV detection show moderate to very good
concordance in referral populations [7, 8], whereas one
study conducted in a screening population reported a
very high level of agreement [9]. Yet, studies on HPV
concordance derive mainly from studies using Hybrid
Capture II (HC2) or in-house Polymerase Chain Reac-
tion (PCR)-based assays [7, 8], while only few studies
have used established, clinically validated PCR-based
HPV DNA assays [9, 10].
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A systematic review demonstrated that self-sampling
is a well-accepted screening method. The main reported
concerns were pain, discomfort touching themselves,
and uncertainty as to whether the sample was collected
correctly [11]. However, in most studies assessing ac-
ceptability, the women obtained the samples in clinics
after face-to-face oral information from healthcare pro-
fessionals, which is not the set-up if self-sampling is to
be implemented in a routine screening program where
self-sampling is to be home-based [11].
Aims
This study aimed to measure concordance in HPV de-
tection between paired self-samples collected at home
using the Evalyn Brush device and general practitioner
(GP)-collected samples, when using the clinically vali-
dated Cobas 4800 HPV DNA test. Further, we wanted to
measure women’s accept of home-based self-sampling.
Methods
Setting
This study was conducted in the Central Denmark
Region (CDR), which covers 23% of the Danish popu-
lation [12]. Like the rest of the country, this region
has been covered by a nationwide, organized,
free-of-charge cervical cancer screening program since
the late 1990s [13, 14].
Currently, 23–49-year-old women are invited for cer-
vical cancer screening every third year, 50–64-year-old
women every fifth year. A liquid-based cervical cytology
sample is taken at their GP (GP-collected sample). The
primary screening method is microscopic examination
of the cytology sample for 23–59-year-old women; a pri-
mary HPV-DNA check-out test for 60–64-year-old
women [13].
In the CDR, the Department of Pathology at Randers
Regional Hospital handles all cytology and HPV analyses.
As per routine, GPs obtain the sample using a cervical
brush and the brush head is placed in 10 ml SurePath
medium (BD Diagnostics, Burlington, NC) and mailed
to the Pathology Department for further processing and
testing according to guidelines, which for women aged
30–59 is microscopic examination. Women with
high-grade cytological lesions (threshold ASC-H or HSIL
or, AGC, or AIS or malignant tumor cells) are referred
directly for colposcopy. Women diagnosed with ASC-US
undergo routine reflex HPV DNA triage testing using
the cell pellet from 1 mL SurePath medium. ASC-US/
HPV-positive women are referred for colposcopy within
3 months. ASCUS/HPV-negative women are referred
back to the routine screening program. Women with
LSIL are monitored by repeated cytology testing [13].
For HPV DNA analyses, the Cobas 4800 assay (Roche
Diagnostic, Switzerland) is used. This test is a real-time
PCR fully automated method separately detecting HPV16,
HPV18, and 12 other high-risk HPV types (HPV 31, 33, 35,
39, 45, 51, 52, 56, 58, 59, 66, and 68) using the β-globin
gene as an extraction and amplification control [15].
Inclusion of participants
Paired GP-collected samples and cervico-vaginal self-
samples were obtained from 30 to 59-year-old women
diagnosed with low-grade cytological lesions (ASC-US)
within the screening program. As per routine, GP-collected
samples from these women are all analyzed by both micros-
copy and HPV, which is not the case for younger and older
women, or women with other cytological diagnoses [13].
Between June 2015 and December 2016, eligible women
were consecutively identified daily through patient lists
provided by the Department of Pathology. They received
written information about the study and then contacted
the investigator for oral information if they wanted to par-
ticipate. A written and signed informed consent form had
to be mailed back to the investigator before inclusion.
The exclusion criteria were pregnancy, giving birth less
than < 3 months previously, and collecting the self-sample
after colposcopy.
Self-sampling collection, storage, and analysis
The women were sent a self-sampling kit comprising a
brush device (Evalyn® Brush, Rovers Medical Devices B.V.,
Oss, Netherlands), written and picture-based user instruc-
tions showing how to collect the cervico-vaginal sample
using the device, a questionnaire, and a pre-addressed re-
turn envelope.
Upon arrival at the laboratory, the brush head was
placed in 10 ml of SurePath medium (BD Diagnostics,
Burlington, NC), stored overnight at 4 °C, and then vor-
texed for 5 min. A 6.4 ml volume of the self-sample ma-
terial was centrifuged at 3000 x RPM for 20 min at
room temperature. After centrifugation, with super-
natant removed, the cell pellet was placed in 1 mL 25%
ethanol-buffered (TRIS) and stored at -80 °C, until fur-
ther processing. A volume of 6.4 ml was chosen to adjust
for the material volume used for cytology examination
performed on the GP-collected samples.
The self-samples were thawed overnight at 4 °C before
the day of analysis. For analysis, the self-sample (1 ml vol-
ume) was vortexed for 15 s before being placed in test
tubes, being the starting point for the HPV testing. Each
run included four water samples to measure contamin-
ation. All HPV testing was performed following the manu-
facturers’ instructions using a protocol without a sample
pre-heating step which was also the case for the
GP-collected samples. The investigator and the laboratory
personnel performing the HPV testing were blinded to the
HPV results of the GP-collected samples.
Tranberg et al. BMC Infectious Diseases  (2018) 18:348 Page 2 of 7
Questionnaire
The questionnaire included three questions on self-sampling
experience and one on the clarity of the user instructions.
To avoid low frequencies, the responses were grouped into
three groups “Agree” (totally agree or agree), “Disagree” (dis-
agree or totally disagree), and “Do not know”. Multiple re-
sponse answers were not allowed. The women were asked
to record the date they had taken the self-sample, whether
they had had sexual intercourse in between the two sam-
plings, and their partner status (i.e., regular partner). Open
feedback was possible. The data were double-entered into
REDCap [16].
Data on test results
Information on the HPV self-sample test results was ob-
tained through patient lists provided by the Department
of Pathology. Data on the GP-collected HPV test results
and the histological results were retrieved from the na-
tionwide Danish Pathology Data Bank (DPDB), which
has been complete since the late 2000s [17]. Histological
results were available only for women who had tested
HPV-positive in their GP-collected sample and were
classified using the CIN classification, which was
grouped into normal, CIN, CIN1, and CIN2+ (including
CIN2, CIN3/AIS, and carcinoma). To ascertain the
histological result, the most severe diagnosis was used if
more were available.
Sample size
The study was designed to estimate a 95% confidence
interval (CI) with a width of +/− 5%. With an expected
86% sensitivity and 85% specificity of HPV detection
(high-risk HPV types) using the Evalyn Brush and a
PCR-based HPV DNA test, a minimum of 198 women
had to be included [10].
Statistical analyses
The HPV concordance between the paired samples was
assessed using the Kappa statistic (Cohen’s Kappa, κ)
and defined as “Poor” (κ ≤ 0.20), “Fair” (0.21 ≤ κ ≤ 0.40),
“Moderate” (0.41 ≤ κ ≤ 0.60), “Good” (0.61 ≤ κ ≤ 0.80), or
“Very good” (κ ≥ 0.81) [18]. The overall percentage of
agreement between the paired samples was calculated as
the proportion of concordant sample sets divided by the
total number of samples. We calculated the sensitivity and
specificity of HPV detection in the self-samples with cor-
responding 95% CIs based on the binomial distribution
using the GP-collected samples as reference standard.
When assessing the HPV concordance regarding specific
genotypes (HPV16/18 and HPV other), the genotypes
were defined as “HPV16/18” (HPV16 and/or HPV18 in-
cluding those having co-infections with other HPV types)
and “HPV other” (HPV of other types including those hav-
ing co-infections with HPV16/18). Concordance was
determined as at least one identical genotype in both sam-
ples; discordance was determined as no genotype similar-
ities. For continuous data, medians and interquartile
ranges (IQR) were calculated; the Mann Whitney rank
sum test was used to test for differences. Descriptive sta-
tistics (proportions and 95% CIs) were used to measure
the women’s accept of self-sampling. The χ2-test was used
to test for differences in categorical data.
P-values < 0.05 were considered statistically significant.
All statistical analyses were performed using STATA,
version 14 (STATA College).
Ethical approval
The study was approved by the local Ethical Committee
of the Central Denmark Region (journal no.: 1–16–
02-209-15) and by the Danish Data Protection Agency
(journal no.:1–10–72-69-15).
Results
Participant characteristics
From a total of 1110 eligible women, 216 (19.5%)
returned a self-sample. Three women (0.3%) were
excluded because the self-sample was taken after the bi-
opsy, leaving 213 (19.2%) women for analysis.
The included women’s median age was 44 years (IQR:
38–49 years). The majority were aged 40 to 49 years
(n = 113, 53.0%) followed by women aged 30 to 39 years
(n = 59, 27.7%) and 50 to 59 years (n = 41, 19.3%). All
paired GP-collected samples and self-samples were valid
for HPV testing.
The median number of days between the GP-collected
sample and the self-sample was 43 days (IQR: 34–53 days,
range: 13–95 days). Histological results were available
for 46 women, of whom 19 (41.3%) had a normal bi-
opsy, 4 had CIN (not specified) (8.7%), 11 had CIN1
(23.9%), and 12 (26.1%) had CIN2+ (2 CIN2, 9 CIN3,
1 adenocarcinoma).
HPV prevalence and concordance between self-sampling
and GP-sampling
For self-samples, the HPV prevalence (any type) was
24.4% (95% CI: 18.8–30.8%); for GP-collected samples
22.1% (95% CI: 16.7–28.2%) (Table 1). There was good
concordance for HPV detection between the self-samples
and the GP-collected samples (κ: 0.70, 95% CI: 0.58–0.81).
The overall level of agreement was 89.2% (95% CI: 84.2–
93.0%) (Table 1). For HPV detection in self-samples, the
sensitivity was 80.9% (95% CI: 66.7–90.9%) and the speci-
ficity 91.6% (95% CI: 86.3–95.3%) when the GP-collected
sample was used as reference.
A total of 23 women (10.7%) had disconcordant re-
sults. In nine cases, the women were GP-collected sam-
ple HPV-positive/self-sample HPV-negative. For these
women, the median number of days between the two
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samples was insignificantly higher than in women with
concordant sample results (n = 38) (40 versus 35 days,
respectively) (p = 0.20). None of these nine women re-
ported having trouble taking the self-sample, although
one woman responded feeling insecure if she had col-
lected the self-sample correctly. Histological results were
available for eight out of the nine women, of whom five
(62.5%) had no CIN, one (12.5%) had CIN (not speci-
fied), and two women (25.0%) had CIN1. The 12 women
diagnosed with CIN2+ all had HPV detected in their
self-sample.
Fourteen women were GP-collected sample HPV-
negative/self-sample HPV-positive; two of whom (14.2%)
reported no sexual intercourse in the time span separat-
ing the two samples.
The HPV prevalence was insignificantly higher in
self-samples than in GP-collected samples for HPV16/18
(9.4%, 95% CI: 5.8–14.1%) versus (8.0%, 95% CI: 4.7–
12.5%) and HPV of other types (21.1%, 95% CI: 15.8–27.2)
versus (18.3%, 95% CI: 13.4–24.2%) (Table 2). Concord-
ance for HPV16/HPV18 detection between self-samples
and the GP-collected samples was good (κ: 0.73, 95% CI:
0.57–0.90) with overall 95.7% agreement (95% CI: 92.1–
98.0%) (Table 2). For HPV16/18, the sensitivity and speci-
ficity in self-samples as compared with GP-collected sam-
ples was 82.4% (95% CI: 56.7–96.2%) and 96.9% (95% CI:
93.5–98.8%), respectively. For HPV of other types, a good
concordance was seen between self-samples and
GP-collected samples (k = 0.64, 95% CI: 0.51–0.78), with
an overall agreement of 88.7% (95% CI: 83.7–92.6%)
(Table 2). The corresponding sensitivity was 76.9% (95%
CI: 60.7–88.9%); the specificity 91.4% (95% CI: 86.2–
95.1%).
Women’s accept of self-sampling
A total of 212 out of 213 women answered the question-
naire. Self-sampling with the Evalyn Brush was recorded
as easy by 97.2% (95% CI: 93.9–98.9%) (Fig. 1), while 6
(2.8%, 95% CI: 1.0–6.1%) recorded that self-sampling
was not easy. Most women reported that self-sampling
was comfortable (94.8%, 95% CI: 90.9%–97.4%). A total
of 21 (9.9, 95% CI: 6.2–14.7%) women reported uncer-
tainty about performing the self-sample correctly, with
three women reporting that they felt insecure because it
Table 1 Concordance and agreement for HPV detection (any type) between self-samples and GP-collected samples
GP-collected samples κb (95% CI) Agreement
(%) (95% CI)
Sensitivity
(%) (95% CI)
Specificity
(%) (95% CI)HPV any positivea HPV negative Total
n % n % n %
Self-samples
HPV any positivea 38 17.8 14 6.6 52 24.4 0.70 (0.58–0.81) 89.2 (84.2–93.0) 80.9 (66.7–90.9) 91.6 (86.3–95.3)
HPV negative 9 4.2 152 71.4 161 75.6
Total 47 22.1 166 77.9 213 100.0
aHPV any positive: HPV16 and/or HPV18 and/or HPV31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. % = Row percentage
bCohen’s Kappa. “Poor” (κ ≤ 0.20), “Fair” (0.21 ≤ κ ≤ 0.40), “Moderate” (0.41 ≤ κ ≤ 0.60), “Good” (0.61 ≤ κ ≤ 0.80), or “Very good” (κ ≥ 0.81) (18)
Table 2 Concordance and agreement between self-samples and GP-collected samples according to specific genotypes
GP-collected samples κa (95% CI) Agreement
(%) (95% CI)
Sensitivity
(%) (95% CI)
Specificity
(%) (95% CI)
HPV 16/18b positive HPV16/18b negative Total
n* % n* % n %
Self-samples
HPV 16/18b positive 14 6.6 6 2.8 20 9.4 0.73 (0.57–0.90) 95.7 (92.1–98.0) 82.4 (56.7–96.2%) 96.9 (93.5–98.8%)
HPV 16/18b negative 3 1.4 190 89.2 193 90.6
Total 17 8.0 196 92.0 213 100
HPV otherc positive HPV otherc negative Total
Self-samples n* % n* % n
HPV otherc positive 30 14.1 15 7.0 45 21.1 0.64 (0.51–0.78) 88.7 (83.7–92.6) 76.9 (60.7–88.9%) 91.4 (86.2–95.1%)
HPV otherc negative 9 4.2 159 74.6 168 78.9
Total 39 18.3 174 81.7 213 100
n* =Women with co-infections with HPV16/18 and HPV of other types appear in both sub-analyses
aCohen’s Kappa. “Poor” (κ ≤ 0.20), “Fair” (0.21 ≤ κ ≤ 0.40), “Moderate” (0.41 ≤ κ ≤ 0.60), “Good” (0.61 ≤ κ ≤ 0.80), or “Very good” (κ ≥ 0.81) (18)
bHPV16/18: HPV16 and/or HPV18 including co-infections with HPV of other types (HPV31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68)
cHPV other: HPV31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 including co-infections with HPV16/18. % = Row percentage
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was difficult to hear the click when rotating the brush.
In 86.8% (95% CI: 81.5–91.0%) of the cases, the women
felt confident that they collected the self-sample cor-
rectly. Most women responded that the user instructions
were clear (97.6%, 95% CI: 94.6–99.2%). There were no
statistically differences between the age groups (p = 0.33)
for any of the questions.
Discussion
Main findings
Our study showed good concordance in HPV detection
between paired self-samples and GP-collected samples.
Home-based self-sampling using the Evalyn Brush was a
well-accepted screening method. Compared with
GP-sampling, no cases of underlying CIN2+ were over-
looked by self-sampling.
Strengths and limitations
A key strength of our study was that we used a combin-
ation of a clinically validated self-sampling device and a
clinically validated automated PCR-based HPV DNA test
assay on paired samples [10, 19]. Furthermore, women
collected the self-sample at home without supervision by
healthcare professionals, which is the most relevant set-
ting for testing self-sampling before its rollout in a rou-
tine screening program.
The main limitation is the time span between the
GP-collected samples and self-samples, making the results
not directly comparable. Still, the questionnaire data helped
us to interpret discordant results. Another explanation for
the discordant results could be that the self-samples had
been subjected to freezing at -80 °C prior to the HPV test-
ing which potentially could have affected the amount of
HPV DNA in the self-samples, unlike the GP-collected
samples which have not been frozen. However, since DNA
is generally considered to be stable at -80 °C, we assume
that this has not significantly affected the results and con-
clusions of this study. Our study population comprised
women with ASC-US of whom one fourth was referred for
colposcopy due to concurrent HPV infection; thus, histo-
logical results were not available for women with
HPV-negative GP-collected samples. Ideally, histological re-
sults should have been available from all women. This was
not possible in our set-up. Still, the available histological re-
sults allowed us to make the important conclusion that no
cases of underlying CIN2+ had been overlooked by
self-sampling which is important when implementing
self-sampling in routine screening practice.
Even though our study population can be considered a
“low-risk” population compared with the referral popula-
tions that have typically been targeted in similar studies
[7], our population is still not representative of a screen-
ing population. Consequently, this study cannot be gen-
eralized to such populations.
Interpretation and comparison with previous studies
The concordance in our study (k = 0.70) was comparable
with the mean k (k = 0.71) reported for brush devices com-
bined with PCR-based HPV DNA tests in the review by
Schmeink et al. [7], but higher than the mean k (k = 0.66)
in the review by Petiginat et al. [8]. This difference might be
explained by differences in self-sampling devices, HPV
tests, laboratory protocols, and study populations (screen-
ing or referral population). In our study, some of the dis-
crepancy in the HPV concordance between self-sampling
and GP-sampling could plausibly also be explained by
spontaneous clearance or a new HPV exposure due to the
time span separating the samples.
Fig. 1 The women’s accept of self-sampling
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In our study, the sensitivity and specificity of HPV de-
tection (of any type) was 80.9% and 91.6% in self-samples,
respectively, when using the GP-collected samples as ref-
erence standard. These results are comparable to those by
Van Baars et al. [10] who found a sensitivity of 82.7% and
a specificity of 89.5% for HPV detection using the Evalyn
Brush together with the clinically validated PCR-based
GP5+/6+ HPV DNA test in a referral population. Thus,
self-sampling using validated HPV DNA analyses seems
feasible, but the optimal combination of self-sample device
and HPV DNA test remains unknown.
Ketelaars et al. [9] found no significant differences in
HPV16/18 prevalence between samples, whereas the
prevalence of HPV of other types was significantly
higher in self-samples (8.0%) than in GP-collected sam-
ples (6.3%). We observed no significant differences in
the HPV prevalence between samples, but the same
trend was seen, especially for the prevalence of HPV of
other types (21.1% versus 18.3%, respectively). The
higher HPV prevalence in self-samples compared with
GP-collected samples increases referral rates, especially
because reflex cytology triage is not possible on
self-sampled material. To avoid excessive referral rates
in women with HPV-positive self-samples without
underlying CIN2+, a direct triage method like DNA
methylation [20] could be considered to reduce referral
rates and prevent overtreatment.
Most importantly, we showed that no underlying
CIN2+ cases were overlooked by self-sampling. Some of
the women in the GP-collected HPV negative/self-sam-
ple HPV-positive group might possibly have had under-
lying CIN2+, but this cannot be explored further in this
study since referral for colposcopy was based on the re-
sult of the GP-collected sample.
The self-sampling device and user instructions must be
acceptable if we wish to improve screening participation
by this method. In our study, more than 85% expressed
confidence in having collected the self-sample correctly,
and only 5% expressed discomfort with collecting the
sample. Hence, home-based self-sampling using the Eva-
lyn Brush appeared to be a well-accepted screening
method. Yet, almost 10% reported uncertainty regarding
sample collection and some stated the lack of a click when
rotating the brush as their reason. Despite small numbers,
this finding is higher than reported by Van Baars et al.
[10] (3.0%) and Ketelaars et al. [9] (0.8%) who used the
same device in a referral and screening population, re-
spectively. This difference might be explained by the fact
that the women in our study performed home-based
self-sampling, whereas in the study by Van Baars et al.
[10] the women performed clinic-based self-sampling
allowing them to ask questions and receive guidance.
Nevertheless, our results suggest that if home-based
self-sampling were to be rolled out in a routine setting, it
should be considered giving women the opportunity to
contact healthcare professionals for guidance.
Conclusions
We report a high acceptability of home-based self-sam-
pling and good concordance between self-samples and
GP-collected samples in terms of HPV detection using
the clinically validated Cobas 4800 HPV DNA test.
Our findings demonstrate the feasibility of offering
self-sampling as an alternative to GP-sampling in
cervical cancer screening.
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